The USTR’s Special 301 Report has been issued every year beginning in 1989. The Executive Summary of the 2009 report says: The “Special 301” Report is an annual review of the global state of intellectual property rights (IPR) protection and… Continue Reading
More on Fabry here: https://keionline.org/fabry NIH rejects Fabrazyme March-In Petition December 7, 2010. Press release from Fabry patients: DHHS denies patient’s march-in request to end Genzyme’s rationing of treatment for Fabry Disease citing that FDA rules block manufactures from supplying… Continue Reading
(More on government funded inventions here: https://keionline.org/government-funded-inventions) On December 9, 2016, the U.S. Army announced its intent to grant an exclusive license to Sanofi on patents for a U.S. Army-developed Zika vaccine. KEI and various other non-profit groups have filed… Continue Reading
Contacting James Love Work phone: +1.202.332.2670 | Mobile Phone +1.202.361.3040 | Email: james.love@keionline.org Twitter: @jamie_love Blue Sky: @jamielove@bsky.social Fediverse: @jameslove@hackyderm.io (Give my office a call or give me another nudge if you have difficulty getting a response. I am overwhelmed… Continue Reading
Below are a few links to pages that show our work in specific fields (note: this list is currently under construction and will be continually updated): Innovation and access to medical technologies Cancer Drugs Coronavirus/COVID-19 Orphan/Rare diseases A standalone page… Continue Reading
The original proposal for the Marrakesh treaty, including the 2008 report of the drafters, is here. web page for Marrakesh diplomatic conference Petitions NFB petition: The Petition Supporting WIPO Treaty for the Blind and Print Disabled https://nfb.org/civicrm/petition/sign?sid=2 ACB petition: Petition… Continue Reading
Sakiko Fukuda-Parr, Chair Sakiko Fukuda-Parr is a Professor of International Affairs at The New School, New York. A development economist, her current work focuses on global policies for human development and human rights in diverse areas including poverty reduction, conflict… Continue Reading
(More on government funded inventions here) 2015 2015: Virotas Biopharmaceuticals. KEI and Public Citizen ask NIH for safeguards in license for HCV patents, April 14, 2015. 2015: NIH refuses to give information about principals in company seeking exclusive license to… Continue Reading
On January 15, 2018, PhRMA provided comments on the Colombian Resolution 5246, a public interest declaration for several drugs for the hepatitis c virus (HCV). A copy of the PhRMA letter is attached below. It is a combination of complaints… Continue Reading
The Cámara de Diputados of the Chilean Congress has overwhelmingly passed a resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. The resolution, Number… Continue Reading